DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities

Abstract

Resistance to chemo- and radiotherapy is a common event among cancer patients and a reason why new cancer therapies and therapeutic strategies need to be in continuous investigation and development. DNA damage response (DDR) comprises several pathways that eliminate DNA damage to maintain genomic stability and integrity, but different types of cancers are associated with DDR machinery defects. Many improvements have been made in recent years, providing several drugs and therapeutic strategies for cancer patients, including those targeting the DDR pathways. Currently, poly (ADP-ribose) polymerase inhibitors (PARP inhibitors) are the DDR inhibitors (DDRi) approved for several cancers, including breast, ovarian, pancreatic, and prostate cancer. However, PARPi resistance is a growing issue in clinical settings that increases disease relapse and aggravate patients’ prognosis. Additionally, resistance to other DDRi is also being found and investigated. The resistance mechanisms to DDRi include reversion mutations, epigenetic modification, stabilization of the replication fork, and increased drug efflux. This review highlights the DDR pathways in cancer therapy, its role in the resistance to conventional treatments, and its exploitation for anticancer treatment. Biomarkers of treatment response, combination strategies with other anticancer agents, resistance mechanisms, and liabilities of treatment with DDR inhibitors are also discussed.

Addressing the gaps in homeostatic mechanisms of copper and copper dithiocarbamate complexes in cancer therapy: a shift from classical platinum-drug mechanisms

“…[234][235][236] Research findings have linked the prochelator's antineoplastic efficiency to cellular GGT activity. 237 A 24-hour survey reports a half maximum inhibitory doses in the range of 800 nM in prostate cancer cell lines 22Rv1 and LNCaP to over 15 µM in normal prostate PWR-1E cells. These findings suggest a novel method for leveraging prostate cancer's…”

Diminished PDE4D7 Expression is Associated with Treatment-Resistant, Lethal Prostate Cancer and Manifests with Impaired Androgen Response, Neuroendocrine Differentiation and Alterations in DNA Repair

“…The targeting of DDR has become increasingly relevant in recent years due to the discovery of deleterious mutations in genes involved in various DDR pathways, which often results in loss of function of the corresponding DNA repair proteins. In particular, the inhibition of PARP1/2 activity has become a cornerstone of treatment for advanced cancers with DDR de ciencies and has been extensively studied in the literature [70]. However, it has also been reported that increase in the gene expression level of DDR genes may lead to resistance to cisplatin chemotherapy [71], while the overexpression of BRCA1, BRCA2, RAD51, and RPA1 has been observed in hypopharyngeal and nasopharyngeal carcinoma cells resistant to radiotherapy [72].…”

The Emerging Burden of Genetic Instability and Mutation in Melanoma: Role of Molecular Mechanisms

“…Cai and his colleagues found that PDPK1i+MEKi is an effective immunostimulatory approach counter to NRAS mutant melanoma. Genetic instability in several types of cancer contributes to acquiring a phenotype needed for colonising distant organs, and metastatic progression correlates with an increase in mutation burden and alteration of genes involved in DNA damage response [ 57 ]. We need to understand better the mechanisms that hinder a cell from tolerating genomic instability and the cellular consequences of exceeding a genomic instability limit…”